Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Precigen stock | $8.33

Own Precigen stock in just a few minutes.

Fact checked

Precigen, Inc is a biotechnology business based in the US. Precigen shares (PGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Precigen employs 770 staff and has a trailing 12-month revenue of around USD$100.8 million.

How to buy shares in Precigen

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Precigen. Find the stock by name or ticker symbol: PGEN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Precigen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$8.33, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Precigen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Precigen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Precigen share price

Use our graph to track the performance of PGEN stocks over time.

Precigen shares at a glance

Information last updated 2020-12-03.
Latest market closeUSD$8.33
52-week rangeUSD$1.26 - USD$8.8
50-day moving average USD$5.5389
200-day moving average USD$4.6927
Wall St. target priceUSD$9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.086

Buy Precigen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Precigen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Precigen price performance over time

Historical closes compared with the close of $8.33 from 2020-12-09

1 week (2021-01-08) -10.43%
1 month (2020-12-17) 1.71%
3 months (2020-10-15) 66.60%
6 months (2020-07-15) 84.29%
1 year (2020-01-15) 22.50%
2 years (2019-01-15) 1.22%
3 years (2018-01-15) N/A
5 years (2016-01-15) 27.11

Precigen financials

Revenue TTM USD$100.8 million
Gross profit TTM USD$-72,558,000
Return on assets TTM -15.11%
Return on equity TTM -122.87%
Profit margin -295.57%
Book value N/A
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting Precigen shares

There are currently 27.1 million Precigen shares held short by investors – that's known as Precigen's "short interest". This figure is 2.6% down from 27.8 million last month.

There are a few different ways that this level of interest in shorting Precigen shares can be evaluated.

Precigen's "short interest ratio" (SIR)

Precigen's "short interest ratio" (SIR) is the quantity of Precigen shares currently shorted divided by the average quantity of Precigen shares traded daily (recently around 856985.36585366). Precigen's SIR currently stands at 31.57. In other words for every 100,000 Precigen shares traded daily on the market, roughly 31570 shares are currently held short.

However Precigen's short interest can also be evaluated against the total number of Precigen shares, or, against the total number of tradable Precigen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Precigen's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Precigen shares in existence, roughly 150 shares are currently held short) or 0.3365% of the tradable shares (for every 100,000 tradable Precigen shares, roughly 337 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Precigen.

Find out more about how you can short Precigen stock.

Precigen share dividends

We're not expecting Precigen to pay a dividend over the next 12 months.

Precigen share price volatility

Over the last 12 months, Precigen's shares have ranged in value from as little as $1.26 up to $8.8. A popular way to gauge a stock's volatility is its "beta".

PGEN.US volatility(beta: 1.7)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precigen's is 1.7018. This would suggest that Precigen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Precigen overview

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Fibrocell Science, Inc.; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Holdings, Inc. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site